Speaker(s): 

Conor Mulcahy DO, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

David Rolston, MD, Resident, Geisinger - has nothing to disclose. 

Learning Objectives: The "Liquid Biopsy": Emphasis on development of the Grail Galleri Test

At the conclusion of this session, the participant should be able to: 

• Review the sequencing technology and biology that make MCED testing possible.
• Describe how the CCGA program identified methylation-based cfDNA as the optimal cancer detection signal.
• Explain how modeling studies estimate potential population-level impact
• Interpret early real-world data (PATHFINDER, Matrana) on test performance and workflows.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Stefanie Leader, DO, Stanley Martin, MD, Dan Dometita, DO, Malachi Courtney, MD, Eric Hossler, DO, Stacey Coolbaugh, RDN, and Donald Weider, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None